PCN21 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS-ANALYSIS STUDIES OF TRASTUZUMAB (HERCEPTIN™) IN TREATMENT OF HER2-POSITIVE BREAST CANCER  by Le, OA
infections in untreated patients = $31; moderate, AWIC = $287;
and severe, AWIC = $4182. CONCLUSION: These data show
IVIG prophylaxis cost $24,512 per patient year, compared to
$4500 with no prophylaxis, or about a 445% increase in cost.
The cost-effectiveness of IVIG in CLL has not been established,
and availability of IVIG is limited. Further studies on other
alternatives, such as prophylactic antibiotic therapy, and impact
on quality of life are needed.
PCN21
SYSTEMATIC REVIEW OF COST-EFFECTIVENESS-ANALYSIS
STUDIES OFTRASTUZUMAB (HERCEPTIN™) INTREATMENT
OF HER2-POSITIVE BREAST CANCER
Le QA
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: There have been numerous studies on cost-
effectiveness of trastuzumab in both treatments of adjuvant and
metastatic breast cancer (BC). Nevertheless, the results reported
were varied depending upon the assumptions and/or perspectives
of the studies. We performed a systematic review of cost-
effectiveness-analysis (CEA) studies of trastuzumab in treatment
of HER2-postive breast cancer. METHODS: Literature search
from 1996 to December 2007 on databases including PubMed,
Ovid MEDLINE, and HealthSTAR was performed to retrieve
CEA studies of trastuzumab, using MESH terms and keywords
such as “trastuzumab,” “costs and cost analysis,” “economics,”
“breast neoplasm,” “cost effectiveness,” “cost utility,” and
“breast cancer.” Additionally, abstracts on CEA studies were also
obtained from American Society of Clinical Oncology (ASCO)
and ISPOR annual meetings. Only CEA studies reported incre-
mental cost-effectiveness ratio (ICER) or cost-utility ratio (ICUR)
as cost per quality-adjusted life years were included in this
review. RESULTS: Thirty ﬁve studies (20 published articles and
15 abstracts) were identiﬁed, of which 18 studies (14 adjuvant, 3
metastatic BC studies, and 1 study of product life-cycle of tras-
tuzumab) representing societal health care perspectives from 12
countries were satisﬁed the criteria. The mean (median) ICERs of
trastuzumab are $24,069/QALY ($23,766/QALY) [ranged from
$4,767 to $58,414/QALY] and $88,373/QALY ($80,000/QALY)
[ranged from $60,120 to $125,000/QALY] for HER2-postive
adjuvant and metastatic breast cancer treatments, respectively.
Majority of sensitivity analyses showed the main cost driver was
the acquisition cost of trastuzumab. In addition, over the product
life-cycle of trastuzumab, the overall ICER is $34,400/QALY
(Garrison et al., 2006). CONCLUSION: This review suggests
that the average costs per QALY of trastuzumab in both treat-
ments of adjuvant and metastatic HER2-positive breast cancer
are consistent and below the suggested cost effectiveness thresh-
old of $100,000/QALY.
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OBJECTIVE: To explore the cost-effectiveness of capecitabine as
adjuvant treatment for Stage III colon cancer. Phase III clinical
trials show that capecitabine improves disease-free survival.
However, these trials involved younger patients than reﬂected
clinically and overall survival was not signiﬁcantly better than
with usual care. We conducted a modeling study comparing
the cost-effectiveness of capecitabine and standard care
(Fluorouracil/Leucovorin (5FU/LV)) in a public-payer context
(Canada), using an older cohort, and with overall survival as the
main outcome. METHODS: A Markov model was developed
to determine the cost-effectiveness of capecitabine compared
with 5FU/LV. The base case was a 70-year-old man after total
mesorectal resection excision of Stage III colon cancer. A ﬁve
year time horizon was used. Health states included treatment
phase, remission, recurrence, disease progression, and death;
throughout the model (except during the active treatment states)
patients could die from other risk-related causes. Ontario health
economic data were used for costs. Probabilities were obtained
from the published literature, and sensitivity analyses were con-
ducted. RESULTS: The base case costs for capecitabine and
5FU/LV were $12,999 and $12,191, respectively. Overall sur-
vival was 4.132 and 4.069 years, respectively. The incremental
cost-effectiveness ratio of capecitabine was $12,821 per life year
gained. However, the incremental cost-effectiveness ratio of
capecitabine was greater than $50,000/life year when the annual
probability of relapse was greater than 0.96 or when drug costs
were assumed to be greater than $1410 per cycle (both values
within the plausible range). CONCLUSION: Capecitabine pro-
duced modestly improved survival over 5FU/LV (0.063 extra
years) with a favourable cost-effectiveness ratio. However,
because the model was sensitive to variations in relapse rate and
drug costs, the relative attractiveness of capecitabine over
5FU/LV is not certain. In addition, utilities and indirect costs
were not considered in the model. Because capecitabine is
administered orally, this could be an important factor warrant-
ing further research.
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OBJECTIVE: Compare two therapy regimens, Lapatinib plus
Capecitabine to Capecitabine alone, for advanced or Metastatic
HER2-positive breast cancer patients who were pretreated with
regimens that included an anthracycline, a taxane, and trastu-
zumab. METHODS: A Markov model, written in Microsoft
Excel(r), is used to simulate progression of breast cancer in a
hypothetical cohort of breast cancer patients in a societal per-
spective. The model consists of three health states: Clinical
Beneﬁts (Response or Stable Disease), Progressive Disease, and
Death. Transitions between health states were assumed to occur
once a month. Life expectancy, costs and QALYs are discounted
monthly by 0.0025% (3% annually). All costs are adjusted to
2007 dollars. RESULTS: Lapatinib plus Capecitabine increases
discounted life expectancy and quality-adjusted life expectancy
by 0.43 years and 0.54 years, respectively, when compared
to Capecitabine alone. This result yields an incremental cost-
effectiveness ratio (ICER) of USD$135,701.69 per QALY (upper
95% CI USD$230,864.99 per QALY), which may be cost effec-
tive, based on the threshold of USD$150,000/QALY. If the value
of Lapatinib price increases at least 13.4%, the combination
therapy is no longer cost-effective. The same outcome is observed
if we increase the transition probability from the Clinical Beneﬁts
state to the Progressive Disease state in the combination therapy
by 12.5% or if we decrease it by 19.3% in monotherapy.
Additionally, by using the 5th percentile of the utility for
Clinical Beneﬁts and the 95th percentile of the utility for
Progressive Disease, the ICER is US$D281,091.34/QALY and
USD$201,232.58/QALY, respectively. CONCLUSION: Based on
a threshold of USD$150,000/QALYs, the treatment with Lapa-
tinib plus Capecitabine is cost-effective in the base case for
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